What's Happening?
Prime Vector Technologies (PVT), a Tübingen-based startup, has developed a novel vector platform based on the Orf virus (ORFV) for vaccines and cancer immunotherapies. Unlike adenoviruses, which are commonly used in viral vector vaccines but can be limited
by pre-existing immunity and cargo capacity, ORFV is considered relatively harmless to humans, causing only localized skin infections that heal without lasting effects. As a poxvirus, ORFV possesses a large linear double-stranded DNA genome, allowing it to carry more than twice the genetic material of adenoviruses. This enables the integration of up to five antigens or a combination of antigens and immunostimulants, such as cytokine genes, to precisely orchestrate the immune response. The platform has demonstrated proof of concept, with the first ORFV-based vaccine, Prime-2-CoV for COVID-19, having successfully completed a Phase I clinical trial and currently undergoing a Phase I/IIa trial. Although the COVID-19 project will not be pursued commercially due to market changes, it provided crucial data on safety, optimal dosage, and immune response.
Why It's Important?
This new Orf virus-based platform represents a significant advancement in vaccine and immunotherapy development. Its high cargo capacity and ability to orchestrate a specific immune response offer greater flexibility and potential efficacy compared to existing viral vector technologies. A key advantage is the absence of a negative effect from pre-existing antibodies against the vector, meaning the technology can be used repeatedly for booster vaccinations or different vaccines. This addresses a major limitation of other viral vectors, which can be neutralized by prior immunity. Furthermore, the thermal stability of ORFV-based vaccines, remaining stable for a month at 25°C and nearly a week at 37°C, makes them suitable for distribution in hard-to-reach or warmer regions, potentially improving global vaccine accessibility. The platform's versatility for prophylactic vaccines, therapeutic vaccines, and oncolytic cancer immunotherapies could lead to a new generation of treatments for a wide range of diseases, including those with pandemic potential.
What's Next?
PVT is actively developing several vaccine candidates using the ORFV platform. A universal influenza vaccine, designed to protect against seasonal influenza and potentially offer several years of protection, is in preclinical development in collaboration with Tübingen University Hospital, with preclinical development expected to conclude by the end of 2027. Another project, in collaboration with the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) and the NMI Natural and Medical Sciences Institute, focuses on a vaccine against human metapneumovirus (hMPV). PVT also has vaccine candidates against pathogens with pandemic potential, such as Marburg, Ebola, and Lassa viruses, in preclinical development. The company plans to manage development up to Phase I or II independently, after which it will seek partners or sell projects for further clinical trials. The long-term goal is to leverage the platform's capabilities to address critical public health needs and prepare for future emergencies, emphasizing societal responsibility over purely commercial motivations.
Beyond the Headlines
The development of the Orf virus platform highlights a broader shift in vaccine research towards more adaptable and robust technologies. The focus on 'orchestrating' the immune system by delivering multiple antigens and immunostimulants simultaneously represents a sophisticated approach to vaccine design, moving beyond simply presenting a single antigen. This could lead to more comprehensive and durable immune responses, particularly important for complex pathogens or cancer. The emphasis on thermal stability and reusability of the vector also addresses critical logistical and accessibility challenges in global health, potentially democratizing vaccine distribution. Furthermore, the dual application of the platform for both infectious diseases and cancer immunotherapies underscores the convergence of research in these fields, leveraging similar immunological principles for diverse therapeutic goals. This innovation reflects a growing recognition that future health security depends on proactive, versatile, and globally accessible biotechnological solutions, moving beyond reactive responses to health crises.
